Academic analysis shows primary care prescribers have been preventing adverse drug reactions, harm, and hospital admissions through the use of safer prescribing technology.
Kent Surrey Sussex Academic Health Science Network (AHSN) carried out an analysis of benefits GPs and other primary care prescribers achieved through the use of a prescribing decision support system called FDB OptimiseRx, currently used in around two thirds of practices in England.
The research aims to begin to build a picture on what progress is being made overall and assess the benefit in primary care from prescribing support and guidance
Focused on a small sample of medicines and associated best-practice alerts issued by the system to general practice prescribers, the analysis showed consistent impact in reducing preventable adverse drug reactions, which have historically been linked with 10% of hospital admissions in older people and a cost to the NHS of £800m per year.
The analysis showed:
- More than 26,000 falls may have been prevented for elderly patients in a single year. The review examined healthcare professionals’ use of the prescribing decision support technology to avoid risky prescription of anticholinergic drugs in elderly patients with dementia or a history of falls, which might then result in potential adverse side effects. These side effects could include impaired cognitive function and further falls. The analysis for 2019/20 calculated that 26,000 falls may have been prevented after it compared the many thousands of times primary care prescribers accepted messages presented through OptimiseRx, against the assessed risk of a fall to patients in question
- Reduced hospital admissions for patients with renal impairment. The OptimiseRx system offers prescribers the opportunity to consider an alternative treatment to using nitrofurantoin - an antibiotic used to treat urinary tract infections for patients with severe renal impairment recorded in their medical record. Nitrofurantoin is not effective in these patients, leading to undertreatment and potential progression to urinary tract infection. Based on the more than 6,500 times prescribers accepted the message, the analysis calculated a reduction in urinary tract infection-related inpatient stays during first-line treatment, representing a potential gross benefit of £575,000 over five years from 2019/20
- Improved quality of life for patients not developing acute kidney injury. Thousands of prescribers accepted a message presented by the system around an increased risk of acute kidney injury (AKI) associated with non-steroidal anti-inflammatory drugs (NSAIDs) when co-prescribed with diuretics and renin-angiotensin system drugs. The review noted that prevention of AKI would lead to improved patient quality of life
- Reduced gastrointestinal bleeds, haemorrhage recurrence and outpatient visits. The analysis also highlighted a marked impact from prescribers accepting OptimiseRx messages to consider prescribing a gastroprotective agent when prescribing a combination of antidepressant selective serotonin reuptake inhibitors (SSRIs) with aspirin or another NSAID. This could help reduce risk of gastrointestinal bleeds, including recurrent haemorrhage, and thus reduce the need for inpatient and outpatient treatment of these gastrointestinal side effects. Studies have shown the detrimental effects of combining SSRIs and NSAIDs
Separately to the AHSN findings, which were commissioned by First Databank (FDB), the company reported that prescribers have now achieved more than £225m of savings through the OptimiseRx system since it was first introduced into the NHS in 2014.
This included £179m through alerting professionals to more-cost-effective medicines, and £46m in costs avoided – such as following NHS England guidance when not to prescribe certain items.
Darren Nichols, managing director at FDB, said: “The issue of reducing severe and avoidable medication harm has been an important global challenge for several years, with ambitious targets by the World Health Organisation to secure action.
“There is a huge estimated cost to the NHS each year from adverse drug reactions, but limited formal data and analysis.
This is a snapshot of what prescribing tech could deliver for safer prescribing at a time when the UK and the world is striving to reduce medicine-related harm
“The research aims to begin to build a picture on what progress is being made overall and assess the benefit in primary care from prescribing support and guidance.”
He added: “In the case of reducing adverse drug reactions, the AHSN analysis has uncovered some significant benefits – ranging from reduced hospital admissions linked to prescribing behaviour around one medicine, to tens of thousands of falls prevented for elderly patients by supporting changes in prescribing decisions.
“This is based on an examination of only a very-small sample of the many thousands of different types of messages presented to staff in primary care every day through the system – a snapshot of what prescribing tech could deliver for safer prescribing at a time when the UK and the world is striving to reduce medicine-related harm.”
